GO:0014056 regulation of acetylcholine secretion, neurotransmission: Synaptic Signaling Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0014056 describes any process that modulates the frequency, rate or extent of the regulated release of acetylcholine, a key neurotransmitter in the central and peripheral nervous systems.
• Acetylcholine secretion is tightly controlled by presynaptic proteins including the vesicular acetylcholine transporter (VAChT), choline acetyltransferase (ChAT), and nicotinic/muscarinic receptors.
• Dysregulation of acetylcholine release is implicated in autism spectrum disorders, Alzheimer's disease, and other neurological conditions.
• Post-translational modifications of nicotinic acetylcholine receptors regulate their function and trafficking, impacting neurotransmission.
• Cortical acetylcholine release is deterministic for attention and learning processes, making it a target for cognitive research.
• CRISPR-based models (knockout, knock-in, overexpression) enable precise dissection of genes regulating acetylcholine secretion.
Description
Regulation of acetylcholine secretion, neurotransmission (GO:0014056) is a biological process that encompasses any mechanism modulating the frequency, rate, or extent of regulated acetylcholine release. Acetylcholine is a major neurotransmitter in both the central and peripheral nervous systems, and its release is essential for processes such as muscle contraction, autonomic function, attention, and memory. The precise control of acetylcholine secretion is achieved through a complex interplay of presynaptic proteins, vesicular transporters, and feedback via autoreceptors. Understanding this regulation is critical because disruptions in cholinergic signaling are associated with neurological disorders including autism spectrum disorders, Alzheimer's disease, and myasthenia gravis. Research into GO:0014056 has revealed that acetylcholine release is not a static process but is dynamically modulated by factors such as vesicular packaging, calcium influx, and receptor-mediated feedback. The vesicular acetylcholine transporter (VAChT) plays a central role by loading acetylcholine into synaptic vesicles, and its regulation directly impacts the amount of neurotransmitter available for release. Moreover, post-translational modifications of nicotinic acetylcholine receptors can alter synaptic transmission efficiency, further highlighting the layers of control. This article synthesizes current knowledge on the mechanisms, key genes, and research methodologies pertinent to GO:0014056, providing a resource for investigators studying cholinergic neurotransmission.
regulation of acetylcholine secretion, neurotransmission At A Glance
| GO ID | GO:0014056 |
|---|---|
| GO term | regulation of acetylcholine secretion, neurotransmission |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the frequency, rate or extent of regulated acetylcholine release |
| Related cellular component | Synaptic vesicle, presynaptic membrane, cholinergic synapse |
| Related molecular function | Vesicular acetylcholine transporter activity, choline acetyltransferase activity |
| Associated genes | SLC18A3 (VAChT), CHAT, CHRNA7, CHRM1, etc. |
| Disease relevance | Autism spectrum disorders, Alzheimer's disease, myasthenia gravis |
What Is GO:0014056?
GO:0014056, regulation of acetylcholine secretion, neurotransmission, is defined as any process that modulates the frequency, rate or extent of the regulated release of acetylcholine. This term captures the regulatory events that control how much acetylcholine is secreted from a neuron or neuroendocrine cell, thereby influencing neurotransmission. It includes presynaptic mechanisms such as vesicle loading, docking, and fusion, as well as feedback regulation by autoreceptors and signaling cascades that adjust release probability.
Why Is regulation of acetylcholine secretion, neurotransmission Important in Cell Biology?
Regulation of acetylcholine secretion is fundamental to nervous system function, influencing everything from muscle activation to cognitive processes like attention and memory. Dysregulation of this process is linked to severe neurological and psychiatric disorders, making it a prime target for therapeutic intervention and basic research.
• Acetylcholine is the primary neurotransmitter at the neuromuscular junction, and its regulated release is essential for voluntary movement.
• In the brain, acetylcholine modulates attention, learning, and memory, with cortical release being deterministic for these functions.
• Impaired acetylcholine secretion is implicated in autism spectrum disorders, as shown in eIF4E transgenic mouse models.
• Neurodegenerative diseases such as Alzheimer's disease involve cholinergic deficits, highlighting the need to understand release regulation.
• Nicotinic acetylcholine receptor post-translational modifications fine-tune neurotransmission, affecting synaptic plasticity.
• The vesicular acetylcholine transporter (VAChT) is a key regulator of quantal release and is a target for genetic manipulation.
• Cholinergic signaling in the adrenal medulla controls stimulus-secretion coupling, relevant to stress responses.
• CRISPR screens can identify novel regulators of acetylcholine secretion, accelerating drug target discovery.
• Understanding GO:0014056 aids in developing treatments for myasthenia gravis and other cholinergic disorders.
• Research on this process benefits from advanced models like knockout mice and patient-derived neurons.
What Happens During regulation of acetylcholine secretion, neurotransmission?
Acetylcholine Synthesis and Vesicular Loading
In simple terms: Acetylcholine is made and packed into tiny bubbles called vesicles.
Acetylcholine is synthesized in the cytoplasm by choline acetyltransferase (ChAT) from choline and acetyl-CoA. It is then transported into synaptic vesicles by the vesicular acetylcholine transporter (VAChT), which is encoded by SLC18A3. This loading process is essential for regulated secretion, as it determines the amount of acetylcholine available for release. VAChT activity is a rate-limiting step in cholinergic neurotransmission, and its regulation directly impacts the frequency and extent of acetylcholine secretion.
Vesicle Docking and Priming
In simple terms: The vesicles get ready to fuse with the cell membrane.
After loading, synaptic vesicles dock at the presynaptic membrane and undergo priming, a process that involves SNARE proteins and other presynaptic machinery. This step prepares vesicles for rapid release upon calcium influx. The regulation of docking and priming is critical for determining the rate of acetylcholine secretion. Synaptogenesis and the assembly of release sites are also important for establishing functional cholinergic synapses.
Calcium-Triggered Fusion and Release
In simple terms: Calcium signals the vesicles to burst and release acetylcholine.
When an action potential arrives, voltage-gated calcium channels open, allowing calcium to enter the presynaptic terminal. Calcium binds to synaptotagmin, triggering the fusion of primed vesicles with the plasma membrane and the release of acetylcholine into the synaptic cleft. This process is tightly regulated to match neuronal activity. In adrenal chromaffin cells, cholinergic stimulation leads to catecholamine secretion through similar calcium-dependent mechanisms.
Feedback Regulation by Autoreceptors
In simple terms: Released acetylcholine can tell the neuron to stop releasing more.
Acetylcholine can bind to presynaptic muscarinic autoreceptors (e.g., M2) to inhibit further release, providing negative feedback. This regulation prevents excessive cholinergic signaling and is a key component of GO:0014056. Nicotinic receptors can also modulate release through post-translational modifications that alter their sensitivity.
Modulation by Post-Translational Modifications
In simple terms: Chemical tags on receptors can change how they work.
Nicotinic acetylcholine receptors undergo various post-translational modifications, including phosphorylation, which can regulate their function and trafficking. These modifications affect receptor desensitization and synaptic transmission, thereby influencing acetylcholine secretion regulation. Such fine-tuning is essential for adapting cholinergic signaling to changing physiological demands.
Key Genes Involved in GO:0014056 regulation of acetylcholine secretion, neurotransmission
The following genes and proteins are central to the regulation of acetylcholine secretion and neurotransmission.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC18A3 (VAChT) | Vesicular acetylcholine transporter; loads acetylcholine into vesicles | Knockout reduces quantal release; target for cholinergic research |
| CHAT | Choline acetyltransferase; synthesizes acetylcholine | Essential for acetylcholine production; mutations cause congenital myasthenic syndromes |
| CHRNA7 | Nicotinic acetylcholine receptor alpha7 subunit | Mediates fast synaptic transmission; linked to schizophrenia and autism |
| CHRM1 | Muscarinic acetylcholine receptor M1 | Modulates cognitive functions; implicated in Alzheimer's disease |
| CHRM2 | Muscarinic acetylcholine receptor M2 | Presynaptic autoreceptor inhibiting release; regulates feedback |
| SLC5A7 (CHT1) | High-affinity choline transporter | Rate-limiting for acetylcholine synthesis; regulates release capacity |
| SYT1 | Synaptotagmin 1; calcium sensor for vesicle fusion | Essential for evoked acetylcholine release |
| SNAP25 | SNARE protein; mediates vesicle fusion | Mutations cause neurodevelopmental disorders |
| STX1A | Syntaxin 1A; SNARE protein | Regulates vesicle docking and fusion |
| VAMP2 | Vesicle-associated membrane protein 2; SNARE protein | Critical for synaptic vesicle exocytosis |
| CACNA1B | Voltage-gated calcium channel N-type | Mediates calcium influx triggering acetylcholine release |
| ACHE | Acetylcholinesterase; degrades acetylcholine | Terminates signaling; target of Alzheimer's drugs |
| CHRNB2 | Nicotinic receptor beta2 subunit | Forms heteromeric receptors; modulates release |
| CHRNA4 | Nicotinic receptor alpha4 subunit | High-affinity nicotine binding; involved in addiction |
| GNAO1 | G protein alpha subunit; modulates calcium channels | Regulates neurotransmitter release; mutations cause movement disorders |
| EIF4E | Translation initiation factor; regulates protein synthesis | Overexpression alters acetylcholine-dopamine balance in autism models |
How Is regulation of acetylcholine secretion, neurotransmission Regulated?
The regulation of acetylcholine secretion is modulated by various signaling pathways. For instance, the eIF4E transgenic mouse model of autism spectrum disorders shows dysregulated acetylcholine-mediated dopamine neurotransmission, indicating that translation initiation factors can impact cholinergic regulation. Additionally, post-translational modifications of nicotinic receptors, such as phosphorylation, provide rapid and reversible control of receptor function, influencing acetylcholine release. Presynaptic autoreceptors and G-protein coupled pathways also fine-tune release probability.
regulation of acetylcholine secretion, neurotransmission and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC18A3 | Congenital myasthenic syndrome | Knockout mouse, patient iPSC-derived neurons |
| CHRNA7 | Schizophrenia, autism | Point mutation knock-in mice, overexpression models |
| ACHE | Alzheimer's disease | Knock-in for human mutations, CRISPR-edited cell lines |
| EIF4E | Autism spectrum disorders | Transgenic overexpression mouse |
| CHAT | Congenital myasthenic syndrome | Knockout and conditional knockout models |
Autism Spectrum Disorders
Dysregulated acetylcholine-mediated dopamine neurotransmission has been observed in the eIF4E Tg mouse model of autism spectrum disorders. This model exhibits altered cholinergic signaling, suggesting that regulation of acetylcholine secretion contributes to the pathophysiology of autism.
Alzheimer's Disease
Alzheimer's disease is characterized by cholinergic deficits, including reduced acetylcholine release. Cortical acetylcholine is deterministic for attention and memory, and its dysregulation is linked to cognitive decline. Therapies targeting acetylcholinesterase aim to boost cholinergic signaling.
Myasthenia Gravis and Neuromuscular Disorders
Myasthenia gravis is an autoimmune disorder affecting nicotinic acetylcholine receptors at the neuromuscular junction, leading to impaired neurotransmission. Regulation of acetylcholine secretion is critical for muscle function, and disruptions cause weakness and fatigue.
Adrenal Medulla Dysfunction
Cholinergic and peptidergic neurotransmission in the adrenal medulla controls stimulus-secretion coupling. Dysregulation can affect stress responses and catecholamine release, with implications for cardiovascular and metabolic disorders.
From regulation of acetylcholine secretion, neurotransmission-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of VAChT affect quantal acetylcholine release? | SLC18A3 knockout mouse or CRISPR KO cell line |
| How do point mutations in CHRNA7 alter receptor function? | Point mutation knock-in mice or CRISPR-edited neurons |
| Can overexpression of EIF4E mimic autism-related cholinergic deficits? | EIF4E transgenic mouse |
| What is the effect of tagging endogenous CHAT on acetylcholine synthesis? | Knock-in of fluorescent tag at CHAT locus |
| Does CRISPR activation of CHRM1 enhance acetylcholine release? | Overexpression via CRISPRa in neuronal cultures |
| How do post-translational modifications regulate nAChR trafficking? | Point mutation knock-in of phosphorylation sites |
How to Study the regulation of acetylcholine secretion, neurotransmission Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Postsynaptic currents or presynaptic release | Assessing synaptic transmission in KO models |
| Amperometry | Real-time quantal release of acetylcholine | Measuring secretion from single cells |
| pHluorin imaging | Vesicle exocytosis and endocytosis | Visualizing release dynamics in neurons |
| CRISPR library screening | Identification of genes regulating secretion | High-throughput discovery of novel regulators |
| Mass spectrometry | Acetylcholine quantification | Validating changes in neurotransmitter levels |
| Immunofluorescence | Localization of cholinergic proteins | Studying receptor trafficking and modifications |
| Western blot | Protein expression and phosphorylation | Assessing post-translational modifications |
| qRT-PCR | mRNA levels of cholinergic genes | Validating knockout or overexpression efficiency |
Electrophysiology
Patch-clamp recordings and amperometry can measure acetylcholine release events in real time. These techniques are used to study quantal release and the effects of genetic manipulations on secretion.
Imaging of Vesicle Dynamics
Fluorescent labeling of synaptic vesicles with pH-sensitive dyes (e.g., pHluorin) allows visualization of vesicle fusion and recycling. This method helps assess how regulators of acetylcholine secretion impact vesicle cycling.
Genetic Screens and CRISPR Libraries
CRISPR knockout or activation libraries can be screened to identify novel regulators of acetylcholine secretion. Such screens often use reporter systems or phenotypic readouts like calcium imaging.
Biochemical Assays
Acetylcholine levels can be quantified using enzymatic assays or mass spectrometry. These methods are useful for validating changes in synthesis and release in knockout or overexpression models.
How CRISPR Can Be Used to Study GO:0014056 regulation of acetylcholine secretion, neurotransmission
Knockout
CRISPR knockout of genes such as SLC18A3 or CHAT can abolish acetylcholine secretion, providing a clean background to study regulatory mechanisms. These models are valuable for dissecting the contribution of specific genes to neurotransmission.
Point Mutation
Introducing point mutations in genes like CHRNA7 or ACHE via CRISPR allows researchers to study the effects of specific amino acid changes on receptor function or enzyme activity. This approach mimics human disease variants and reveals structure-function relationships.
Knock-in
Knock-in of reporter tags (e.g., fluorescent proteins) at endogenous loci such as CHAT enables real-time tracking of protein expression and localization. This technique is useful for studying dynamic regulation of acetylcholine synthesis and release.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of genes like EIF4E can model gain-of-function states associated with disease. Overexpression of EIF4E in mice leads to dysregulated acetylcholine-dopamine neurotransmission, mimicking autism-like phenotypes.
How EDITGENE Supports regulation of acetylcholine secretion, neurotransmission Research
Researchers studying regulation of acetylcholine secretion, neurotransmission-related genes often need to determine whether a candidate gene is causally involved in cholinergic signaling. EDITGENE provides a comprehensive suite of CRISPR services to create precise cellular and animal models, enabling functional validation of genes implicated in GO:0014056.
Contact EDITGENE today to design your custom CRISPR model for regulation of acetylcholine secretion, neurotransmission research.
Frequently Asked Questions About regulation of acetylcholine secretion, neurotransmission
What is GO:0014056?
GO:0014056 is a Gene Ontology term for the biological process 'regulation of acetylcholine secretion, neurotransmission', which encompasses any process that modulates the frequency, rate or extent of regulated acetylcholine release.
What genes are involved in regulation of acetylcholine secretion?
Key genes include SLC18A3 (VAChT), CHAT, CHRNA7, CHRM1, CHRM2, SLC5A7, SYT1, SNAP25, and others involved in vesicle loading, fusion, and feedback.
How is acetylcholine secretion regulated?
Acetylcholine secretion is regulated at multiple levels: synthesis by ChAT, vesicular loading by VAChT, calcium-triggered vesicle fusion, and feedback via presynaptic autoreceptors.
What diseases are associated with dysregulated acetylcholine secretion?
Dysregulation is linked to autism spectrum disorders, Alzheimer's disease, myasthenia gravis, and adrenal medulla dysfunction.
What is the role of VAChT in acetylcholine secretion?
VAChT (SLC18A3) loads acetylcholine into synaptic vesicles, a rate-limiting step for regulated release. Its regulation directly impacts quantal size and neurotransmission.
How do post-translational modifications affect acetylcholine neurotransmission?
Post-translational modifications of nicotinic acetylcholine receptors, such as phosphorylation, can alter receptor function, trafficking, and desensitization, thereby modulating neurotransmission.
Can CRISPR be used to study acetylcholine secretion?
Yes, CRISPR knockout, knock-in, and overexpression models enable precise manipulation of cholinergic genes to study their roles in acetylcholine secretion and neurotransmission.
What model organisms are used to study regulation of acetylcholine secretion?
Common models include mice (e.g., VAChT knockout, EIF4E transgenic), Drosophila, and patient-derived iPSC neurons.
What is the eIF4E mouse model of autism?
The eIF4E transgenic mouse overexpresses translation initiation factor eIF4E and exhibits dysregulated acetylcholine-mediated dopamine neurotransmission, modeling autism spectrum disorders.
How does cortical acetylcholine affect attention?
Cortical acetylcholine release is deterministic for attention and learning, with its regulation being critical for cognitive functions.
Conclusion
Regulation of acetylcholine secretion, neurotransmission (GO:0014056) is a vital biological process that controls cholinergic signaling in health and disease. The interplay of synthesis, vesicular loading, calcium-triggered release, and feedback mechanisms ensures precise neurotransmission. Dysregulation of this process contributes to autism, Alzheimer's disease, and myasthenia gravis, underscoring its clinical relevance. Advances in CRISPR-based models and screening technologies are accelerating the discovery of novel regulators, offering new therapeutic avenues. EDITGENE's comprehensive services support researchers in dissecting the genetic and molecular basis of acetylcholine secretion regulation.
References
- 1. Carbonell-Roig J et al.. 2024. Dysregulated acetylcholine-mediated dopamine neurotransmission in the eIF4E Tg mouse model of autism spectrum disorders.. Cell Rep 43(12):114997 PMID: 39607825
- 2. Chrestia JF et al.. 2023. Regulation of nicotinic acetylcholine receptors by post-translational modifications.. Pharmacol Res 190:106712 PMID: 36863428
- 3. Petzoldt AG et al.. 2014. Synaptogenesis.. Curr Biol 24(22):R1076-80 PMID: 25458214
- 6. Prado VF et al.. 2013. Regulation of cholinergic activity by the vesicular acetylcholine transporter.. Biochem J 450(2):265-74 PMID: 23410039
- 7. Sarter M et al.. 2014. Deterministic functions of cortical acetylcholine.. Eur J Neurosci 39(11):1912-20 PMID: 24593677
- 8. Guérineau NC. 2020. Cholinergic and peptidergic neurotransmission in the adrenal medulla: A dynamic control of stimulus-secretion coupling.. IUBMB Life 72(4):553-567 PMID: 31301221
